Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 10/20 | 0.39 |
| ▸ | CASP7 | P55210 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140997 | 0.91 | USP30 (0.39) | CASP3CASP7KCNH2HRH3DRD3 | |
| SCHEMBL4128188 | 0.87 | KCNH2 (0.39) | KCNH2HRH3DRD2DRD3 | |
| SCHEMBL4136270 | 0.85 | BACE1 (0.38) | CASP3CASP7KCNH2HRH3DRD2 | |
| SCHEMBL4141846 | 0.82 | DRD2 (0.35) | KCNH2HRH3DRD2DRD3 | |
| SCHEMBL4133535 | 0.81 | HRH3 (0.43) | KCNH2HRH3 | |
| SCHEMBL4144558 | 0.81 | MCHR1 (0.41) | KCNH2HRH3 | |
| SCHEMBL4141749 | 0.80 | MLNR (0.37) | DRD2DRD3 | |
| SCHEMBL4130700 | 0.79 | ALDH1A1 (0.39) | DRD2DRD3 | |
| SCHEMBL4145757 | 0.79 | MCHR1 (0.43) | CASP3KCNH2DRD2DRD3 | |
| SCHEMBL4139555 | 0.78 | GPR84 (0.40) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | CASP3 2504/4885CASP7 2473/4885KCNH2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.